Sign in Subscribe
Class action lawsuits

Class Action Lawsuit Filed Against Rocket Pharmaceuticals, Inc.

Strategic Insights

— 1 min read

Rocket Pharmaceuticals, Inc. investors who bought the company's stocks between September 17, 2024, and May 26, 2025, may be affected by a class action securities lawsuit alleging securities fraud. The lawsuit claims that the company provided false and misleading statements about the safety and clinical trial protocol of its RP-A501 treatment, leading to artificially inflated stock prices. On May 27, 2025, Rocket announced a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event (SAE), leading to a significant decline in stock price.

Key Takeaways:

  • The lawsuit alleges that Rocket Pharmaceuticals provided false and misleading statements about the safety and clinical trial protocol of its RP-A501 treatment, leading to artificially inflated stock prices.
  • The company amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders.
  • On May 27, 2025, Rocket announced a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event (SAE), leading to a significant decline in stock price.
  • The stock price of Rocket's common stock decreased from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day.
  • Investors have until August 11, 2025, to request that the Court appoint them as lead plaintiff.
  • There is no cost or obligation to participate in the class action lawsuit.
  • Levi & Korsinsky, LLP has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.

Statistics:

  • Number of shares: Rocket's common stock based on the company's last reported available share count from its May 9, 2025, stock split.
  • Stock price decline: 37% in the span of just a single trading day.
  • Price on May 23, 2025: $6.27 per share.
  • Price on May 27, 2025: $2.33 per share.

Sources:

  • Source: Levi & Korsinsky, LLP (August 5, 2025)
  • Source: Twitter.

Read more